• The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to speed their completion and boost domestic supply, under an executive order signed Monday by President Donald Trump.
• The order also seeks to increase inspections of overseas manufacturing plants supplying the U.S. market funded by increased fees “to the extent consistent with applicable law.” The FDA will disclose the annual number of overseas inspections by country and by manufacturer.
• Big pharma companies this year have announced investment of more than$170 billion in new manufacturing facilities in the U.S. as they seek to consolidate their supply chains and avoid potential new tariffs.Public comments are due Wednesday on a Commerce Department investigation on the national security risks of drug and ingredient imports, which could set the stage for new sector-wide tariffs.

My Thoughts 💭